famotidine has been researched along with Celiac Disease in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Celiac Disease: A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We carried out a long-term prospective study in an attempt to clarify the effectiveness of the associated use of famotidine to enzymatic supplementation on fat absorption and nutritional parameters of patients with pancreatic insufficiency due to cystic fibrosis." | 9.07 | Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. ( Averna, MR; Carroccio, A; Iacono, G; Iapichino, L; Montalto, G; Notarbartolo, A; Pardo, F; Soresi, M, 1992) |
| " We carried out a long-term prospective study in an attempt to clarify the effectiveness of the associated use of famotidine to enzymatic supplementation on fat absorption and nutritional parameters of patients with pancreatic insufficiency due to cystic fibrosis." | 5.07 | Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. ( Averna, MR; Carroccio, A; Iacono, G; Iapichino, L; Montalto, G; Notarbartolo, A; Pardo, F; Soresi, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carroccio, A | 1 |
| Pardo, F | 1 |
| Montalto, G | 1 |
| Iapichino, L | 1 |
| Soresi, M | 1 |
| Averna, MR | 1 |
| Iacono, G | 1 |
| Notarbartolo, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)[NCT03551691] | Phase 2 | 19 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for famotidine and Celiac Disease
| Article | Year |
|---|---|
Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis.
Topics: Adolescent; Celiac Disease; Child; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Famotidine; F | 1992 |